通化金马上半年净利润同比增长34.77%，正在开展新药上市申请有关工作

Core Viewpoint - Tonghua Golden Horse (000766) reported a slight increase in revenue and a significant rise in net profit for the first half of 2025, indicating a positive trend in financial performance despite a challenging market environment [1][2]. Financial Performance - The company achieved an operating income of 650 million yuan, a year-on-year increase of 0.12% [1]. - The net profit attributable to shareholders was 16.804 million yuan, reflecting a year-on-year growth of 34.77% [1]. - The net profit after deducting non-recurring gains and losses was 14.4073 million yuan, showing a substantial increase of 125.07% year-on-year [1]. - Basic earnings per share were reported at 0.02 yuan [1]. Business Overview - Tonghua Golden Horse is primarily engaged in the research, production, and sales of pharmaceutical products, with a diverse product range covering oncology, microbiology, cardiovascular, detoxification, digestive, musculoskeletal, gynecological, and neurological systems [1]. - The company operates through various business units, including its headquarters, Shengtai Biological, Yongkang Pharmaceutical, and Yuanshou Biological [1]. Research and Development - The company focuses on enhancing professional skills and quality research levels, aiming to improve its technological innovation capabilities and market influence [2]. - Tonghua Golden Horse is developing a self-researched national class 1.1 new drug, Succinic Dihydrogenated Aminoacridine Tablets, which has received a notice of acceptance for its market application from the National Medical Products Administration [2][3]. - The drug is intended for the treatment of mild to moderate Alzheimer's disease and has undergone various clinical trial phases since 2007 [3]. Regulatory and Market Position - The company is actively working on the registration and market launch of Succinic Dihydrogenated Aminoacridine Tablets, adhering to relevant laws and guidelines [2][3]. - The drug's approval process is currently ongoing, with the company maintaining communication with the Center for Drug Evaluation (CDE) to address any inquiries during the review process [3].